



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

07th November 2020

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager-Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref - Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 07th November 2020, has approved the following

1. Statement of unaudited financial results, (Standalone) for the quarter and half year ended 30th September 2020. (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II).
3. Appointment of Mr. Vadla Nagbhushanam (DIN-08863512) as Independent Director (Additional) with immediate effect. (Annexure-III)
4. Acceptance of Resignation of Mr. Kashinath Iyer as Independent Director with immediate effect due to their preoccupation and other personal reasons. (Annexure-IV).

The Meeting Commenced on 12:30 p.m. and Concluded on 03:00 p.m.

The above information will be made available on the Company's website www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You

Yours faithfully,
For Nath Bio-Genes (India) Limited


Devinder Khurana
Chief Financial Officer



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 6 MONTHS ENDED 30/09/2020

		Rs in Lacs					
S. No.	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30/09/2020 Unaudited	30/06/2020 Unaudited	30/09/2019 Unaudited	30/09/2020 Unaudited	30/09/2019 Unaudited	31/03/2020 Audited
I	Income						
	(a) Revenue from operations	2326.38	19325.08	2136.42	21651.46	18668.36	27989.05
	(b) Other Operating Income	45.14	39.57	32.49	84.71	95.37	182.25
	Total Income	2371.52	19364.65	2168.91	21736.17	18763.73	28171.30
II	Expenses						
	a) Cost of Material Consumed	3441.63	4270.19	1511.39	7711.82	6116.97	16714.88
	b) Purchase of Stock-in-Trade	452.64	12.53	25.00	465.17	158.04	734.82
	c) Changes in Inventory of Finished Goods & Work in Progress	(3598.18)	5491.19	(1433.83)	1893.01	2204.31	(4824.61)
	d) Employee Benefit Expense	398.19	508.79	339.21	906.98	736.57	1873.72
	e) Finance Costs	201.40	197.56	148.68	398.96	321.74	654.60
	f) Depreciation & Amortisation Expenses	67.17	66.65	37.50	133.82	72.50	145.26
	g) Selling & Distribution Expenses	570.22	4019.46	614.48	4589.67	4199.29	5948.29
	h) Admin & R&D Expenditure	522.00	643.06	545.88	1165.06	1027.21	2073.50
	Total Expenses	2055.06	15209.43	1788.31	17264.49	14836.63	23320.45
III	Profit before Exceptional Items & Tax (I - II)	316.46	4155.22	380.60	4471.67	3927.10	4850.85
IV	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00
V	Profit Before Tax (III+IV)	316.46	4155.22	380.60	4471.67	3927.10	4850.85
VI	Tax Expense						
	(a) Current Tax	15.08	29.46	5.71	44.54	26.46	16.06
	(b) Earlier Year Tax	0.00	0.00	5.78	0.00	5.78	(216.65)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	3.03
VII	Not Profit for the period (V-VI)	301.38	4125.76	369.11	4427.13	3894.86	5048.40
VIII	Other Comprehensive Income						
	1 (a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	44.75
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	44.75
IX	Total Comprehensive Income for the period (VII + VIII)	301.38	4125.76	369.11	4427.13	3894.86	5003.65
X	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XI	Reserves (excluding Revaluation Reserves) as per balance sheet of previous	58288.45	57987.07	52752.52	58288.45	52752.52	53861.32
XII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	1.59	21.71	1.94	23.30	20.49	26.33

NOTES:

(1) The financial results were reviewed by the Audit Committee in meeting held on 05 November 2020 and were thereafter approved by the Board of Directors at its meeting held on 07 November 2020.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation.

(3) There was no major impact of COVID 19 on operations of the Company. The plants were operational with special permission from the appropriate authorities. However, the production and logistics were affected to certain extent. Market also felt the brunt of Pandemic due to restricted lifting of material.


(4) The figures have been regrouped/rearranged where ever necessary.

FOR NATH BIO-GENES (INDIA) LTD


Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad

Date : 07 Nov 2020


Nath Bio-Genes (India) Limited		
Standalone Statement of Assets and Liabilities		
		Rs. In Lacs
Particulares	As at Half Year end 30.09.2020 (Unaudited)	As at Year end 31.03.2020 (Audited)
A ASSETS		
(1) Non Current Assets		
a) Property, Plant & Equipment	23084.82	23086.32
b) Capital Work in Progress	0.00	0.00
c) Other Intangible Assets	1436.71	1516.50
d) Intangible Assets under Development	0.00	0.00
e) Financial Assets		
(i) Investments	504.75	499.75
(ii) Loans	21.60	22.08
(iii) Others	0.00	0.00
f) Deferred Tax Assets (Net)	69.37	69.37
g) Other Non Current Assets	100.00	84.41
Total Non Current Assets	25217.25	25278.44
(2) Current Assets		
a) Inventories	17415.20	20430.81
b) Financial Assets		
(i) Investments	0.00	0.00
(ii) Trade Receivables	12157.08	10700.28
(iii) Cash and Cash Equivalentents	2038.68	2197.99
(iv) Bank balance other than (iii) above	0.00	0.00
(v) Loans	13307.18	13460.81
c) Current Tax Assets (Net)	760.60	760.46
d) Other Current Assets	210.62	165.79
Total Current Assets	45889.37	47716.13
TOTAL ASSETS	71106.62	72994.57
B EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
(a) Share capital	1900.40	1900.40
(b) Reserves and Surplus	58288.45	53861.32
(c) Money received against share warrants	0.00	0.00
Sub-total - Shareholders' Fund	60188.85	55761.72
2. Share application money pending for allotment	0.00	0.00
3. Minotiries Interest	0.00	0.00
4. Non-current liabilities		
a) Long Term Borrowings	65.42	29.96
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	0.00	0.00
d) Long Term Provisions	320.95	240.90
Sub-total - Non-current liabilities	386.37	270.86
5. Current Liabilities		
a) Short Term Borrowings	7881.51	6950.50
b) Trade Payables	1463.98	6820.57
c) Other Current Liabilities	860.40	2852.38
d) Short Term Provisions	37.07	94.62
e) Current Tax Liabilities	288.45	243.92
	10531.40	16962.00
TOTAL - EQUITY AND LIABILITIES	71106.62	72994.57
FOR NATH BIO-GENES (INDIA) LTD		
		
Satish Kagliwal MANAGING DIRECTOR DIN 00119601		
Place : Aurangabad		
Date : 07 November 2020		

Nath Bio-Genes (India) Limited

Cash Flow Statement for the Half Year Ended 30.09.2020

Particulars	Half Year ended	Year ended
	30.09.2020 (Unaudited)	31.03.2020 (Audited)
A) CASH FLOW FROM OPERATING ACTIVITIES		
Nett Profit before Tax & Extra Ordinary items	4,427.13	4,850.85
Adjustment for :		
Depreciation	133.82	145.26
Provision for Gratuity	51.93	80.71
Provision for Compensated Absences	28.12	28.97
Interest Paid / Financial Charges	398.96	654.60
Provisoin (Reversal of Provision) for Bad Debts	0.00	-32.77
Profit on sale of Fixed Assets	-0.37	-12.83
Loss on Sale of Fixed Assets	0.00	10.14
Expenses under Other Comprehensive Income	0.00	-44.75
Interest Income	-55.11	-130.19
Operating Profit before working capital changes	4,984.48	5,549.99
Adjustment for :		
(Increase) / Decrease in Trade Receivables	-1,456.80	134.99
(Increase) / Decrease in Inventories	3,015.61	-4,895.19
(Increase) / Decrease in Loans & Advances	153.49	-1,595.82
(Increase) / Decrease in Other Current Assets	-44.83	32.92
Increase / (Decrease) in Trade Payable	-5,356.60	1,800.44
Increase / (Decrease) in other current liabilities	-2,004.99	72.04
	-5,694.13	-4,450.62
Cash Generated from operation before Tax & Extra Ordinary item	-709.65	1,099.37
Income tax Paid	0.00	-151.95
Net Cash Flow from Operating Activities - (A)	-709.65	947.42
B) CASH FLOW FROM INVESTING ACTIVITIES		
Sale of fixed assets	2.80	46.45
Purchase of Fixed Assets (Tangible)	-54.93	-423.77
Purchase of Fixed Assets (In Tangible)	0.00	-1,196.57
Interest Received	55.11	130.19
Purchase of Non Current Investment	-5.00	-0.02
Net Cash Flow from Investing Activities - (B)	-2.02	-1,443.72
C) CASH FLOW FROM FINANCING ACTIVITIES		
Interest Paid / Financial Charges	-398.96	-654.60
(Increase) / Decrease in Long Term Assets	-15.11	0.00
Increase / (Decrease) in Long Term Borrowings	35.46	-20.50
Increase / (Decrease) in Long Term Provisions	0.00	0.00
Increase / (Decrease) in Short Term Borrowings	931.00	1,134.85
Increase / (Decrease) in Short Term Unsecured Loans	0.00	96.59
Nett Cash Flow From Financing Activities - (C)	552.39	556.34
Nett increase/Decrease in cash & cash equivalent (A+B+C)	-159.28	60.04
Opening Cash and Cash Equivalent	2,197.97	2,137.93
CLOSING CASH & CASH EQUIVALENT	2,038.69	2,197.97

FOR NATH BIO-GENES (INDIA) LTD



Satish Kagliwal
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad
Date : 07 Nov 2020

ASHOK R. MAJETHIA

BCom. F.C.A
CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.
Chartered Accountants
Utsav Complex,
Office No. 7, Bazar Peth,
Dist. Raigad, Khopoli – 410 203
Tel :- (02192) 269908
Mobile :- 9404711539 / 9372169952
Email :- ashokmajethia@redifmail.com

LIMITED REVIEW REPORT


To,
The Board of Directors
Nath Bio-Genes (India) Limited
Aurangabad

1. We have reviewed the accompanying statement of unaudited financial results of Nath Bio-Genes (India) Limited for the quarter ended 30th September 2020 and year to date results for the period 1st April 2020 to 30th September 2020 ("The Statement") being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ashok R Majethia
Chartered Accountants
FRN: 127769W


Ashok Majethia
Proprietor
M No: 124781
UDIN: 20124781AAAACR3044



Place: Khopoli
Date: 7th November 2020



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Annexure-

Appointment of Mr. Vadla Nagbhushanam as Independent Director (additional).

Date of Appointment	07 th November 2020
Designation	Independent Director (additional)
Terms and Condition	Regular
Qualification	Bachelor of Commerce
Brief Profile and Experiences	Mr. Nagbhushanam is a Commerce Graduate he has have over 30 years of rich experience in the field of Agriculture, Management and finance with various industries. He is presently placed in Andhra Pradesh, the hub center of agricultural activities.
Related to Director	Not Applicable

[Handwritten Signature]

NATH SEEDS
अ बीज खरा, शक्ति भरा

- Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com
- 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

**NATH
GROUP**

From:

Kashinath Ganapathy Iyer
Flat No B-6,
Shant Ganga Complex
State Bank of India ke pass
Aurangabad-431001

Date- 02/11/2020

To,
The Board of Directors,
Nath Bio-Genes (India) Limited
Nath House, nath road
Aurangabad-431005

Subject- Resignation from the post of Director of the Company.

Dear Sir,


I hereby tender my resignation from the Directorship of the Company due to preoccupation and personal reasons. Kindly relive me from the post of Director of the Company with effect from 07th November 2020.

I hereby confirm that there are no other material reasons other than those provided above.

I would like to take this opportunity to convey my thanks to the Board for giving me opportunity of being associated with the Company.

Thanking You,

Yours faithfully



Kashinath Ganapathy Iyer
DIN-01195975